Condition

Metastatic Castration-resistant Prostate Cancer (mCRPC) clinical trials and research

• 19Clinical trials
• 1New in 30 days
• 46Countries

Newest Metastatic Castration-resistant Prostate Cancer (mCRPC) clinical trials

All recruiting trials (19)

• GI-102 with Pasritamig for metastatic prostate cancer

  This trial tests GI-102 together with Pasritamig to see if it is safe and may help men whose metastatic castration-resistant prostate cancer has progressed after prior hormonal therapy.

  Recruiting at 5 sites Phase 1/2 GI Innovation, Inc. · New York, New York and 5 other locations · NCT07871435

• Exploring Terbium-161 PSMA Therapy for Advanced Prostate Cancer

  This phase 1 study tests 161Tb-PSMA-I&T to see if it is safe and how it behaves in Taiwanese men with metastatic castration-resistant prostate cancer.

  Recruiting at 2 sites Phase 1 National Taiwan University Hospital · Taipei and 1 other locations · NCT07621692

• REGN15505 Alone or With Cemiplimab or REGN4336 in Advanced Prostate Cancer and Kidney Cancer

  This trial tests REGN15505 by itself or with cemiplimab or REGN4336 to see if it helps adults with metastatic castration-resistant prostate cancer or clear cell renal cell carcinoma.

  Recruiting at 6 sites Phase 1/2 Regeneron Pharmaceuticals · Goodyear, Arizona and 5 other locations · NCT07594106

• Oral INR731 alone or with androgen receptor blockers for metastatic castration-resistant prostate cancer

  This tests whether oral INR731 by itself or with androgen receptor pathway inhibitors is safe, tolerable, and shows early anti‑tumor activity in adults with metastatic castration‑resistant prostate cancer.

  Recruiting at 13 sites Phase 1 Novartis · Boston, Massachusetts and 12 other locations · NCT07570979

• Cannabidiol for Pain Relief in End-Stage Metastatic Castration-Resistant Prostate Cancer

  This study tests whether cannabidiol (CBD) can reduce opioid use and relieve pain in men with end-stage metastatic castration-resistant prostate cancer.

  Recruiting Phase 2 Regionshospital Nordjylland · Gistrup · NCT07549256

• Lu‑177 PSMA‑3D1015 injections for men with metastatic castration‑resistant prostate cancer

  This trial will test Lu‑177 PSMA‑3D1015 injections in adult men with PSMA‑positive metastatic castration‑resistant prostate cancer to see if the treatment is safe and shows anti-tumor activity.

  Recruiting Phase 1 Affiliated Hospital of Jiangnan University · Wuxi, Jiangsu · NCT07537010

• Xaluritamig in adults with metastatic castration-resistant prostate cancer

  A new drug called xaluritamig is being tested in adults with metastatic castration-resistant prostate cancer to see if it is safe with the planned dosing.

  Recruiting at 14 sites Phase 1 Amgen · Denver, Colorado and 13 other locations · NCT07493512

• Lutetium-177 DGUL plus pembrolizumab in metastatic castration-resistant prostate cancer

  This study tests whether adding pembrolizumab to Lutetium-177 DGUL is safe and can help treat men with advanced prostate cancer that no longer responds to hormone therapy.

  Recruiting Phase 1 Cellbion Co., Ltd. · Seoul · NCT07244393

• KTX-2001 (alone and with darolutamide) for men with metastatic castration‑resistant prostate cancer

  This trial tests whether KTX-2001, by itself and combined with darolutamide, can help men whose prostate cancer has spread and stopped responding to hormone therapies.

  Recruiting at 13 sites Phase 1 K36 Therapeutics, Inc. · San Francisco, California and 12 other locations · NCT07103018

• Green tea and quercetin with docetaxel for metastatic castration-resistant prostate cancer.

  This will test whether adding green tea and quercetin to docetaxel chemotherapy helps men with metastatic castration-resistant prostate cancer more than docetaxel with a placebo.

  Recruiting Phase 1/2 Charles Drew University of Medicine and Science · Los Angeles, California · NCT06615752

• Evaluating YL201 for treating advanced prostate cancer

  This study is testing a new injection treatment called YL201 to see if it can help people in China with advanced prostate cancer feel better and improve their condition.

  Recruiting at 2 sites Phase 2 MediLink Therapeutics (Suzhou) Co., Ltd. · Hefei, Anhui and 23 other locations · NCT06241846

• Comparing Opevesostat to Other Hormonal Treatments for Advanced Prostate Cancer

  This study tests if a new treatment called opevesostat, combined with hormone therapy, can help men with advanced prostate cancer live longer and feel better compared to other hormonal treatments they might have already tried.

  Recruiting at 297 sites Phase 3 Merck Sharp & Dohme LLC · Tucson, Arizona and 329 other locations · NCT06136650

• PROVENGE® followed by one sipuleucel‑T booster for metastatic castration‑resistant prostate cancer

  This trial tests whether giving one booster infusion of sipuleucel‑T to men with metastatic castration‑resistant prostate cancer who already completed PROVENGE® can boost their immune response and remain safe.

  Recruiting at 30 sites Phase 2 Dendreon · Tuscon, Arizona and 30 other locations · NCT06134232

• Combining antibiotics with enzalutamide for advanced prostate cancer treatment

  This study is testing whether combining antibiotics with enzalutamide can help men with advanced prostate cancer feel better and fight their disease.

  Recruiting at 2 sites Phase 1/2 Institute of Cancer Research, United Kingdom · Bellinzona and 1 other locations · NCT06126731

• Zanzalintinib with immune checkpoint drugs for advanced solid tumors

  This trial will test whether zanzalintinib alone or combined with immune drugs (nivolumab, with or without ipilimumab or relatlimab) is safe and helps people with advanced or metastatic solid tumors such as renal cell, prostate, urothelial, and liver cancers.

  Recruiting at 101 sites Phase 1 Exelixis · Phoenix, Arizona and 121 other locations · NCT05176483

• Evaluating NX-1607 for advanced cancers

  This study is testing a new treatment called NX-1607 to see if it can help people with advanced cancers who have run out of other options.

  Recruiting at 15 sites Phase 1 Nurix Therapeutics, Inc. · Duarte, California and 16 other locations · NCT05107674

• Evaluating the safety and effectiveness of REGN5678 alone or with cemiplimab for advanced prostate and kidney cancer

  This study is testing if a new drug called REGN5678, alone or with another drug called cemiplimab, can safely shrink tumors in adults with advanced prostate and kidney cancer.

  Recruiting at 26 sites Phase 1/2 Regeneron Pharmaceuticals · Gilbert, Arizona and 26 other locations · NCT03972657

• Biomarker-driven treatment for metastatic prostate cancer

  This study is testing if personalized treatments based on specific genetic markers can help people with advanced prostate cancer feel better compared to standard care.

  Recruiting at 29 sites Phase 3 Karolinska Institutet · Aalst and 31 other locations · NCT03903835

• Treatment of advanced cancers with Mevrometostat

  This study is testing a new drug called Mevrometostat to see if it can help people with advanced cancers like small cell lung cancer, prostate cancer, and follicular lymphoma feel better and improve their treatment outcomes.

  Recruiting at 22 sites Phase 1 Pfizer · Tucson, Arizona and 84 other locations · NCT03460977

Related topics

Quick answers

How many Metastatic Castration-resistant Prostate Cancer (mCRPC) clinical trials are recruiting right now?

19, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 46 countries. The most sites are in United States (11 trials), South Korea (6 trials), Australia (4 trials), China (4 trials), Spain (4 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 9, Phase 1/2: 5, Phase 2: 3, Phase 3: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →